Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530388 | 0.90 | L3MBTL1 (0.40) | ALDH1A1TP53CYP3A4HPGDTSHR | |
| SCHEMBL2532268 | 0.88 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTLMNAPKM | |
| SCHEMBL2537785 | 0.86 | ITGA4 (0.36) | ALDH1A1TP53CYP3A4HPGDTSHR | |
| SCHEMBL2530387 | 0.78 | L3MBTL1 (0.40) | ALDH1A1HPGDSMN1; SMN2MAPTPOLB | |
| SCHEMBL29434843 | 0.78 | L3MBTL1 (0.40) | ALDH1A1HPGDSMN1; SMN2MAPTPOLB | |
| SCHEMBL2532560 | 0.74 | ALDH1A1 (0.35) | ALDH1A1CYP3A4TSHRSMN1; SMN2HIF1A | |
| SCHEMBL3131907 | 0.72 | ALDH1A1 (0.60) | ALDH1A1TSHRSMN1; SMN2MAPTPOLB | |
| SCHEMBL4438662 | 0.72 | ATM (0.37) | ALDH1A1TSHRSMN1; SMN2HIF1AMAPT | |
| SCHEMBL4438665 | 0.72 | ATM (0.37) | ALDH1A1TSHRSMN1; SMN2HIF1AMAPT | |
| SCHEMBL3536336 | 0.72 | ALDH1A1 (0.69) | ALDH1A1TSHRSMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754240-B2 | Process for the manufacture of 4-fluoro-2-methyl-1H-indol-5-ol | ASTRAZENECA AB (SE) | 2014-06-17 | — | — | US | disclosed |
| EP-2540706-A2 | PROCESS FOR PREPARING INDOL-5-OXY-QUINAZOLINE DERIVATIVES AND INTERMEDIATES | AstraZeneca AB (Publ) (SE) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540705-A2 | Process for preparing indol-5-oxy-quinazoline derivatives and intermediates | AstraZeneca AB (Publ) (SE) | 2013-01-02 | — | — | EP | disclosed |
| CN-101528688-B | Process for preparing indole-5-oxoquinazoline derivatives and intermediates | ASTRAZENECA AB | 2012-09-05 | — | — | CN | disclosed |
| CN-102584798-A | Process for preparing indol- 5 -oxy- quinazoline derivatives and intermediates | ASTRAZENECA AB | 2012-07-18 | — | — | CN | disclosed |
| CN-102532108-A | Process for preparing indol-5-oxy-quinazoline derivatives and intermediates | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-20110257395-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2011-10-20 | — | — | US | disclosed |
| US-7851623-B2 | Chemical process | ASTRAZENECA AB (SE) | 2010-12-14 | — | — | US | disclosed |
| EP-2129657-A2 | PROCESS FOR PREPARING INDOL-5-OXY-QUINAZOLINE DERIVATIVES AND INTERMEDIATES | AstraZeneca AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| CN-101528688-A | Process for preparing indole-5-oxoquinazoline derivatives and intermediates | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | disclosed |
| US-20080221322-A1 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008053221-A2 | PROCESS FOR PREPARING INDOL- 5 -OXY- QUINAZOLINE DERIVATIVES AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257395-A1 | Chemical Process | CYP3A5, CYP3A4, CYP3A7 | ALDH1A1 609/4885TP53 3014/4885CYP3A4 2/4885 |
| US-20080221322-A1 | CHEMICAL PROCESS | CYP3A5, CYP3A4, CYP3A7 | ALDH1A1 609/4885TP53 3014/4885CYP3A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.